
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax Inc. is maintaining a positive outlook as it has slightly increased its FY25 revenue framework from $1-$1.05 billion to $1.04-$1.06 billion, bolstered by anticipated milestone earnings and marketing authorization transfers. The company's working capital has improved significantly to $544.7 million, providing additional liquidity to fund operations and focus on core competencies. Furthermore, strategic cost reduction initiatives are projected to yield approximately $230 million in savings over the next 11 years, enhancing financial stability and operational efficiency.
Bears say
Novavax Inc is experiencing a significant downturn in its financial outlook, highlighted by a $160M decrease in cash equivalents during 2024, which raises concerns about operational sustainability amid ongoing cash burn. The company has reported a 17% year-over-year revenue decline due to the transition of lead commercial responsibility to Sanofi beginning with the upcoming COVID season, leading to substantial reductions in income. Furthermore, the potential failure of its vaccine candidates, such as NanoFlu, to differentiate from existing options poses a risk to their competitiveness, which could negatively impact future revenue generation and overall valuation.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares